Posted on BioWorld Aug. 18
This could explain the panic selling with 1 million common shares and one million warrants issued at .05 . Keep in mind that these are incentive warrants because the company met targets. That should actually bring shareholder confidence that the unicorn is within reach. Give it a read...... Toronto-based Therma Bright Inc. completed phase I due diligence on Orpheus Medica Inc.s platform technology and plan for the development of a rapid saliva test, Covisafe, for the detection of COVID-19. Covisafe will integrate Orpheus' biologics and advanced computational platforms, coupled with third party device technology, to develop a reliable palm-sized rapid test for COVID-19 screening. As a result of completing phase I due diligence, Therma Bright has issued to Toronto-based Orpheus 1 million Therma common shares and 1 million warrants exercisable at $0.05 per share with a 5-year expiry.